IP Library Granted Patent US 7,550,158
Granted Patent B2
US 7,550,158 · App. 10/799,536 · Granted Jun 23, 2009

Controlled release by extrusion of solid amorphous dispersions of drugs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,550,158
App. No.
10/799,536
Granted
Jun 23, 2009
Kind
B2
Abstract

Controlled release dosage forms for low solubility drugs are disclosed wherein an amorphous solid dispersion of the drug is coated with a non-dissolving and non-eroding coating that controls the influx of water to the core so as to cause extrusion of a portion of the core, as well as a method of treating a disease or disorder comprising administering such dosage form to a person.

Claims (14)

1. A controlled release dosage form, comprising:

(a) a core, having a drug layer composition and a sweller layer composition in a bi-layer geometry, comprising an osmotic agent contained in the sweller layer composition and, contained in the drug layer composition, a low solubility drug in the form of a solid dispersion of said drug in a dispersion polymer, wherein substantially all of said drug is amorphous, and wherein said drug in said solid dispersion exhibits amorphous character in at least one of x-ray diffraction analysis or differential scanning calorimetry; and

(b) a water-permeable coating around said core having at least one delivery port therein, said coating controlling the influx of water to said core from an aqueous environment of use to cause extrusion of at least a portion of said core through said at least one delivery port to said aqueous environment of use, said coating being non-dissolving and non-eroding during release of said drug;

wherein said dispersion polymer is selected from the group consisting of hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethylcellulose acetate phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, and carboxymethylethylcellulose

wherein said dosage form provides at least one of the following AUC in drug concentration selected from (i) and (ii):

(i) an AUC in drug concentration in a use environment that is at least 1.25-fold that of a control dosage form comprising an identical dosage form containing an equivalent quantity of undispersed drug, and

(ii) when said dosage form is dosed orally to a mammal, said dosage form provides an AUC in drug concentration in the blood that is at least 1.25-fold that of a control dosage form comprising an identical dosage form except containing an equivalent quantity of undispersed drug.

2. The dosage form of claim 1 wherein said solid dispersion is homogeneous.

3. The dosage form of claim 1 further comprising an osmotically effective solute.

4. The dosage form of claim 1 wherein said osmotic agent comprises a water-swellable hydrophilic polymer that is separate from said dispersion polymer.

5. The dosage form of claim 4 wherein said water-swellable hydrophilic polymer is selected from the group consisting of hydrophilic vinyl and acrylic polymers, polysaccharide alginates, poly(ethylene oxide), polyethylene glycol, polypropylene glycol, poly(2-hydroxyethyl methacrylate), poly(acrylic) acid, poly(methacrylic) acid, polyvinyl pyrrolidone, crosslinked, polyvinyl pyrrolidone, polyvinyl alcohol, polyvinyl pyrrolidone/polyvinyl alcohol copolymers, vinyl acetate, hydrophilic polyurethanes containing large polyethylene oxide blocks, carrageenan, hydroxethyl-cellulose, hydroxypropylcellulose, hydroxypropylmethyl-cellulose, carboxymethylcellulose, carboxyethylcellulose, sodium alginate, polycarbophil, gelatin, xanthan gum, sodium croscarmellose, and sodium starch glycolate.

6. The dosage form of claim 1 wherein said solid dispersion is formed by spray-drying said low-solubility drug and said dispersion polymer together in a solvent.

7. The dosage form of claim 1 wherein said dispersion polymer is hydroxypropylmethyl cellulose acetate succinate.

8. The dosage form of claim 1 wherein said drug is selected from the group consisting of an anti-hypertensive, an antianxiety agent, an anticlotting agent, a blood glucose-lowering agent, a decongestant, an antihistamine, an antitussive, an anti-inflammatory, an anti-atherosclerotic agent, an antipsychotic agent, a cognitive enhancer, a cholesterol-reducing agent, an antiobesity agent, an autoimmune disorders agent, a hypnotic agent, an anti-Parkinsonism agent, an antibiotic, an antiviral agent, an anti-impotence agent, an anti-neoplastic, a sedative, a barbituate, a nutritional agent, a beta-blocker, an emetic, an anti-emetic, a diuretic, an anticoagulant, a cardiotonic, an androgen, a corticoid, an anabolic agent, an anti-depression agent, an anti-infective agent, a coronary vasodilator, a carbonic anhydrase inhibitor, an antifungal, an antiprotozoal, a gastrointestinal agent, a dopaminergic agent, an anti-Alzheimer's Disease agent, an anti-ulcer agent, a platelet inhibitor, and a glycogen phosphorylase inhibitor.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2008
From: PFIZER INC.; PFIZER PRODUCTS INC.
To: BEND RESEARCH, INC.
Reel/Frame 021998/0880 →